Flagship Pioneering 在伦敦设立实验室,打造 AI 原生公司
Flagship Pioneering Launches London Lab to Build AI-Native Companies
Flagship Pioneering 于 2026 年 11 月 16 日宣布在伦敦设立 Flagship Origination Lab, U.K.,初始投入 1 亿英镑,这是其首个美国以外的公司创建单元。该实验室将聚焦人类与地球健康,计划招募并培训约 50 名科学家创业者与运营人员,并通过合作再引入 5 亿英镑。Flagship 称过去 25 年已创建超过 130 家公司,包括 Moderna。
正文
Flagship Pioneering announced on November 16, 2026 that it is establishing Flagship Origination Lab, U.K. in London, backed by an initial £100 million commitment. The lab will conceive, test, fund and build AI-native platform companies, and is Flagship’s first dedicated company-creation unit outside the United States.
Operating within Flagship Labs, the London unit will focus on human and planetary health and other frontiers of science and technology. It brings a company-creation model developed in Cambridge, Massachusetts, into a locally rooted UK ecosystem connected to Flagship’s global organization.
Founder and CEO Noubar Afeyan said Flagship anticipates scaling its commitment through partnerships to attract an additional £500 million. The additional amount depends on future partnerships and remains separate from the capital committed at launch.
Flagship expects to recruit and train approximately 50 scientist-entrepreneurs and operators for the initial UK team. The local company-creation ecosystem will remain connected to the broader organization, including its Pioneering Intelligence and Pioneering Medicines business units.
Flagship’s model starts with scientific questions and develops them into platforms, products and companies. The firm says it has created more than 130 companies over more than 25 years, including Moderna, providing the company-creation record it is now extending to the UK.
Avak Kahvejian, president of Flagship Labs and a general partner at Flagship Pioneering, described origination as a discipline led by teams of scientist-entrepreneurs who “begin with bold questions about what could be possible.” The London team will accordingly be involved in generating and testing ideas as well as financing and building the resulting companies.
That structure gives Flagship a role from the earliest stage of company formation. Rather than operating solely as an investor in existing startups, the lab is designed to originate the underlying scientific platforms and then build businesses around them within its own ecosystem.
The UK Foundation for the Expansion
The launch follows three years of Flagship partnering and conducting R&D across the UK. It opened a London office and signed a memorandum of understanding with the UK government in 2023 to extend the global reach and impact of its companies.
Flagship describes Quotient Therapeutics, launched during that period, as its first transatlantic company. Its UK activity also includes clinical trials involving Flagship-founded companies such as Generate:Biomedicines, alongside partnerships across academia, data and regulatory innovation.
Kahvejian said the UK’s science base, clinical-trial infrastructure, genomics and health-data assets, agile regulatory environment, and scientists and entrepreneurs made it a deliberate choice for the expansion. Those resources provide the foundation on which Flagship intends to build its local company-creation operation.
Chris McDonald MP, Minister for Science, Innovation and Investment, said the government wants more AI and life-sciences businesses to turn research and technology into jobs and economic growth, with Flagship’s commitment helping new UK companies take breakthroughs to international markets.
The expansion adds local company origination to Flagship’s existing UK research, partnerships and clinical activity. Its larger financial ambition depends on attracting partners, while the lab’s operational test is whether the new team can turn those scientific and clinical assets into new AI-native companies.